Please login to the form below

Not currently logged in
Email:
Password:

Paula Hensler joins 90TEN as scientific team lead

She will lead the London-based healthcare comms consultancy's editorial team

90TEN Paula HenslerLondon-based healthcare communications consultancy 90TEN has appointed Paula Hensler as scientific team lead to head up its editorial team.

She joins the firm after a two-year spell freelancing as a medical writer and med ed consultant that saw her work with the likes of Pulse, the British Journal of Cardiology, Reynolds-Mackenzie, and Luther Pendragon.

A hospital doctor by training, Hensler has previously served as clinical editor of GP magazine, editor of MIMS Oncology & Palliative Care and director of medical conferences at Haymarket Medical.

90TEN has also appointed Kate Haynes, who joins from Chameleon Communications International to take up a role as a senior medical writer

Victoria Boswell-Smith, a director at 90TEN, said: “Editorial excellence coupled with creative visualisation is at the centre of everything we do. With their wealth of experience, we are delighted to secure Paula and Kate to help drive this moving forward."

The addition of Hensler and Haynes to its team follows 90TEN's appointment in September of Rosie Pigott, who joined from Darwin Healthcare as a senior account executive.

3rd November 2015

From: Marketing

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics